BlackRock Group’s Rigel Pharmaceuticals RIGL Stock Holding History

BlackRock Group’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$181K	Hold	7,615	–	–	﹤0.01%	2688
2016 Q3	$279K	Hold	7,615	–	–	﹤0.01%	2511
2016 Q2	$170K	Hold	7,615	–	–	﹤0.01%	2634
2016 Q1	$158K	Hold	7,615	–	–	﹤0.01%	2640
2015 Q4	$231K	Buy	7,615 +408	+6%	+$12.4K	﹤0.01%	2479
2015 Q3	$178K	Hold	7,207	–	–	﹤0.01%	2562
2015 Q2	$231K	Buy	7,207 +4,298	+148%	+$164K	﹤0.01%	2540
2015 Q1	$104K	Sell	2,909 -19,883	-87%	-$545K	﹤0.01%	2646
2014 Q4	$517K	Sell	22,792 -37,033	-62%	-$749K	﹤0.01%	2218
2014 Q3	$1.16M	Buy	59,825 +2,196	+4%	+$62K	﹤0.01%	1693
2014 Q2	$2.09M	Buy	57,629 +41,151	+250%	+$1.4M	﹤0.01%	1443
2014 Q1	$639K	Sell	16,478 -137	-0.8%	-$4.88K	﹤0.01%	2158
2013 Q4	$474K	Hold	16,615	–	–	﹤0.01%	2242
2013 Q3	$595K	Buy	16,615 +2,567	+18%	+$93.7K	﹤0.01%	2155
2013 Q2	$470K	Buy	+14,048	New	+$637K	﹤0.01%	2066

Other funds holding RIGL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BlackRock Group's RIGL Position: Q4 2016 in Review

BlackRock Group held its Rigel Pharmaceuticals (RIGL) position steady in Q4 2016 at 7,615 shares worth $181K. The position accounts for ﹤0.01% of the portfolio, ranked #2688.

BlackRock Group first reported a position in RIGL in Q2 2013 and has held it in 15 quarters since. The position peaked at $2.09M in Q2 2014. 107 funds tracked by Wall St. Rank hold RIGL as of Q4 2016.

BlackRock Group held 7,615 shares of Rigel Pharmaceuticals worth $181K as of Q4 2016.
BlackRock Group left its Rigel Pharmaceuticals share count unchanged in Q4 2016.
Rigel Pharmaceuticals made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2688 holding.
BlackRock Group first reported a position in Rigel Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
BlackRock Group's Rigel Pharmaceuticals position peaked at $2.09M in Q2 2014.
107 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.